<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Gut</journal-id><journal-id journal-id-type="iso-abbrev">Gut</journal-id><journal-id journal-id-type="hwp">gutjnl</journal-id><journal-id journal-id-type="publisher-id">gut</journal-id><journal-title-group><journal-title>Gut</journal-title></journal-title-group><issn pub-type="ppub">0017-5749</issn><issn pub-type="epub">1468-3288</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24131637</article-id><article-id pub-id-type="pmc">4033276</article-id><article-id pub-id-type="publisher-id">gutjnl-2013-305606</article-id><article-id pub-id-type="doi">10.1136/gutjnl-2013-305606</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Hepatology</subject></subj-group><series-title>Original article</series-title></article-categories><title-group><article-title>Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Manousou</surname><given-names>Pinelopi</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cholongitas</surname><given-names>Evangelos</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Samonakis</surname><given-names>Dimitrios</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tsochatzis</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Corbani</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dhillon</surname><given-names>A P</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>Janice</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez-Per&#x000e1;lvarez</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Patch</surname><given-names>D</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>O'Beirne</surname><given-names>J</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thorburn</surname><given-names>D</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Luong</surname><given-names>TuVinh</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rolles</surname><given-names>K</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Davidson</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>McCormick</surname><given-names>P A</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hayes</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Burroughs</surname><given-names>Andrew K</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><institution>The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af2"><label>2</label><addr-line>Department of Histopathology</addr-line>, <institution>Royal Free Hospital</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af3"><label>3</label><addr-line>Transplant Unit</addr-line>, <institution>Royal Infirmary of Edinburgh</institution>, <addr-line>Edinburgh</addr-line>, <country>UK</country></aff><aff id="af4"><label>4</label><addr-line>Liver Unit</addr-line>, <institution>St Vincent's University Hospital</institution>, <addr-line>Dublin</addr-line>, <country>Ireland</country></aff><author-notes><corresp><label>Correspondence to</label> Professor Andrew K Burroughs, The Royal Free Sheila Sherlock Liver Centre and University Department of Surgery, UCL and Royal Free Hospital, Pond Street, Hampstead, London NW3 2QG, UK; <email>Andrew.Burroughs@nhs.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2013</year></pub-date><volume>63</volume><issue>6</issue><fpage>1005</fpage><lpage>1013</lpage><history><date date-type="received"><day>9</day><month>7</month><year>2013</year></date><date date-type="rev-recd"><day>6</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="gutjnl-2013-305606.pdf"/><abstract><sec><title>Objective</title><p>Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8&#x02005;years of follow-up, including differences in fibrosis assessed by collagen proportionate area (CPA).</p></sec><sec><title>Design</title><p>103 consecutive liver transplant recipients with HCV cirrhosis receiving cadaveric grafts were randomised to tacrolimus MT (n=54) or TT (n=49) with daily tacrolimus (0.1&#x02005;mg/kg divided dose), azathioprine (1&#x02005;mg/kg) and prednisolone (20&#x02005;mg), the last tailing off to zero by 6&#x02005;months. Both groups had serial transjugular biopsies with hepatic venous pressure gradient (HVPG) measurement. Time to reach Ishak stage 4 was the predetermined endpoint. CPA was measured in all biopsies. Factors associated with HCV recurrence were evaluated. Clinical decompensation was the first occurrence of ascites/hydrothorax, variceal bleeding or encephalopathy.</p></sec><sec><title>Results</title><p>No significant preoperative, peri-operative or postoperative differences between groups were found. During 96&#x02005;months median follow-up, stage 4 fibrosis was reached in 19 MT/11 TT with slower fibrosis progression in TT (p=0.009). CPA at last biopsy was 12% in MT and 8% in TT patients (p=0.004). 14 MT/ three TT patients reached HVPG&#x02265;10&#x02005;mm&#x02005;Hg (p=0.002); 10 MT/three TT patients, decompensated. Multivariately, allocated MT (p=0.047, OR 3.23, 95% CI 1.01 to 10.3) was independently associated with decompensation: 14 MT/ seven TT died, and five MT/ four TT were retransplanted.</p></sec><sec><title>Conclusions</title><p>Long term immunosuppression with tacrolimus, azathioprine and short term prednisolone in HCV cirrhosis recipients resulted in slower progression to severe fibrosis assessed by Ishak stage and CPA, less portal hypertension and decompensation, compared with tacrolimus alone.</p></sec><sec><title>ISRCTN94834276</title><p>&#x02014;Randomised study for immunosuppression regimen in liver transplantation.</p></sec></abstract><kwd-group><kwd>LIVER TRANSPLANTATION</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text position="float"><caption><title>Significance of this study</title></caption><sec><title>What is already known on this subject?</title><list list-type="bullet"><list-item><p>Immunosuppression worsens severity of recurrence of HCV after liver transplantation.</p></list-item><list-item><p>There are very few studies and only one randomised study assessing immunosuppressive protocols on different severity of recurrence of chronic HCV hepatitis.</p></list-item></list></sec><sec><title>What are the new findings?</title><list list-type="bullet"><list-item><p>Triple therapy with tacrolimus, azathioprine and tapering steroids resulted in less fibrosis progression compared with tacrolimus monotherapy, contrary to the initial hypothesis, that less immunosuppression should reduce progression of HCV recurrent disease.</p></list-item><list-item><p>Triple therapy also resulted in less progression of clinically significant portal hypertension (hepatic venous pressure gradient &#x02265;10&#x02005;mm&#x02005;Hg) and less clinical decompensating events (ascites, bleeding, varices, encephalopathy).</p></list-item><list-item><p>Discontinuation of azathioprine resulted in further fibrosis progression compared with continuation of azathioprine.</p></list-item><list-item><p>The fibrosis progression with triple therapy is the lowest recorded in the literature.</p></list-item></list></sec><sec><title>How might it impact on clinical practice in the foreseeable future?</title><list list-type="bullet"><list-item><p>This trial obliges a review of immunosuppressive protocols in patients transplanted with HCV cirrhosis. The use of azathioprine should be considered.</p></list-item><list-item><p>Azathioprine and other immunosuppressive agents need to be tested in HCV replicon systems to assess if there is a direct antiviral effect and in cell systems for any potential immunological interaction with profibrotic and antifibrotic mechanisms.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>We published early results of a randomised trial in liver transplant recipients with HCV cirrhosis assessing tacrolimus monotherapy (MT) versus tacrolimus, azathioprine and prednisolone triple therapy (TT), which showed a slower onset of histological severe fibrosis and portal hypertension in the TT arm compared with tacrolimus alone, independent of other factors known to affect fibrosis.<xref rid="R1" ref-type="bibr">1</xref> This was contrary to the starting hypothesis that the lesser immunopotency with MT should result in less fibrosis.</p><p>However, despite our initial trial results and other consistent data with more patients,<xref rid="R2" ref-type="bibr">2&#x02013;4</xref> including a possible benefit with azathioprine,<xref rid="R5" ref-type="bibr">5</xref> the optimal immunosuppression for HCV transplant recipients is still debated.<xref rid="R6" ref-type="bibr">6</xref> Indeed, immunosuppression worsens the severity of HCV recurrence.<xref rid="R6" ref-type="bibr">6</xref> Cyclosporine has no advantage versus tacrolimus regarding stage progression<xref rid="R7" ref-type="bibr">7</xref> despite in vitro (but not in vivo) activity against HCV.<xref rid="R8" ref-type="bibr">8</xref> Tacrolimus compared with cyclosporine improves both patient and graft survival including patients transplanted for hepatitis C cirrhosis<xref rid="R6" ref-type="bibr">6</xref> and is the preferred calcineurin inhibitor.</p><p>Therefore, we evaluated outcomes in our trial, after a median of 8&#x02005;years of follow-up, including the original end points as well as differences in hepatic venous pressure gradient (HVPG) and collagen proportionate area (CPA) as a quantitative measure of fibrosis and clinical decompensation.</p></sec><sec sec-type="methods" id="s2"><title>Patients and methods</title><sec id="s2a"><title>Inclusion&#x02014;exclusion criteria, randomisation and endpoints</title><p>From January 2000 to June 2007, at the Royal Free Hospital, consecutive transplant recipients were randomised if they had cirrhosis, were HCV RNA positive in serum and previous histology was compatible with HCV liver disease. Randomisation at the Royal Edinburgh Infirmary and St Vincent's University Hospital was between 12/2003 and 5/2006. Inclusion and exclusion criteria were published previously.<xref rid="R1" ref-type="bibr">1</xref> The study protocol was approved by the Hospital Ethics committees at each site.</p><p>Follow-up stopped at death, retransplantation or 1/2013. We analysed the original primary endpoints&#x02014;progression to Ishak stage 4 and graft failure either resulting in retransplantation or patient's death. We also evaluated patients&#x02019; survival, acute cellular rejection episodes, chronic rejection, recurrence of HCV (defined by Ishak inflammation score&#x02265;4), HVPG progression to 10&#x02005;mm&#x02005;Hg, CPA, fibrosis progression assessed by CPA and Ishak stage (for comparison with other published studies), and time to first episode of clinical decompensation defined as whichever occurred first, of ascites/hydrothorax, variceal bleeding or encephalopathy.</p><p>For each patient, the following were evaluated: demographic and clinical data (including concomitant hepatocellular carcinoma (HCC) and/or alcoholic aetiology), donor age/gender, cold/warm ischaemia time, initial immunosuppression and subsequent changes, occurrence and treatment of rejection episodes, cytomegalovirus or other infections, histological episodes of de novo hepatitis, genotype, viral load pre-LT and 1&#x02005;year post-liver transplantation (LT), antiviral treatment and sustained virological response (SVR), diabetes mellitus pretransplant and post-transplant, human leucocyte antigen and blood group compatibility of donor/recipient, sex match/mismatch and tacrolimus levels at 5, 15 and 30&#x02005;days post-LT.</p></sec><sec id="s2b"><title>Immunosuppression regimens</title><p>The MT group received tacrolimus 0.1&#x02005;mg/kg/day (two divided doses). The TT group received the same tacrolimus dosing, together with azathioprine&#x02014;initially intravenously then orally&#x02014;1&#x02005;mg/kg/day, and methylprednisolone (16&#x02005;mg/day intravenous) until oral intake was established (20&#x02005;mg/day prednisolone). Tacrolimus trough concentrations were evaluated on alternate week days. The doses were adjusted to maintain a whole blood level within 5&#x02013;14&#x02005;ng/mL (aiming for 5&#x02013;10). Azathioprine was continued at the same starting dose unless neutropenia developed: 16 patients discontinued azathioprine between 10 and 37&#x02005;months (median 14&#x02005;months) post-LT. Prednisolone was gradually tapered from 3&#x02005;weeks onwards and then stopped between 3 and 6&#x02005;months, according to each centre's practice. Protocol biopsies were undertaken to diagnose acute cellular rejection between days 5 and 10. If moderate or severe rejection was diagnosed, daily intravenous 1&#x02005;gm methylprednisolone was given for 3&#x02005;days.<xref rid="R9" ref-type="bibr">9</xref></p></sec><sec id="s2c"><title>Virological assays</title><p>Determination of HCV genotype was performed by reverse transcription PCR and reverse hybridisation assay of the amplified sequence (InnoLipa HCV II, Innogenetics, Zwijnaarde, Belgium).<xref rid="R10" ref-type="bibr">10</xref></p><p>Qualitative tests were performed by a reverse transcription PCR assay (Amplicor HCV, Roche Diagnostic Systems Inc, Branchburg, New Jersey, USA&#x02014;later Bayer Thermomechanical Analyzer Component system, Berkeley, California, USA).<xref rid="R11" ref-type="bibr">11</xref></p></sec><sec id="s2d"><title>Liver biopsies</title><p>Protocol liver biopsies were performed at yearly intervals and also if clinically indicated. All liver biopsies were reviewed by liver trained histopathologists in each centre, in a blinded fashion.</p><p>Liver biopsy samples were formalin fixed, paraffin embedded and stained with H&#x00026;E, Gordon and Sweet staining was used for reticulin and Sirius red and Van Gieson stains were used in Edinburgh. All biopsies at the Royal Free Hospital were restained with picroSirius Red to ensure comparable staining for collagen quantification and determination of CPA by digital image analysis. The stage of disease (fibrosis 0&#x02013;6) and the grade of necroinflammatory activity were evaluated according to Ishak <italic>et al</italic>.<xref rid="R12" ref-type="bibr">12</xref></p><p>The number of liver cores, length of biopsy (lengths of each core summed), and portal tract number per core and in total were recorded.<xref rid="R13" ref-type="bibr">13</xref> Liver biopsies&#x0003c;12&#x02005;mm long were excluded (29 of 310). Complete portal tracts were defined according to Crawford and colleagues.<xref rid="R14" ref-type="bibr">14</xref> The equipment used and CPA measurement were performed as previously described.<xref rid="R15" ref-type="bibr">15</xref></p><p>Acute cellular rejection was graded using the Royal Free Hospital score.<xref rid="R16" ref-type="bibr">16</xref> Histological de novo hepatitis (HDNH) C termed &#x02018;histological acute hepatitis C&#x02019; previously<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R2" ref-type="bibr">2</xref> was defined as before as an increase in alanine aminotransferase levels (&#x0003e;2 upper normal limit), together with histological changes consistent with hepatitis without diagnostic features of cellular rejection, duct loss or other cause of liver injury, including alloimmune hepatitis (autoantibodies negative).<xref rid="R2" ref-type="bibr">2</xref></p><p>Fibrosis progression in each patient was calculated by percentage change of fibrosis according to CPA (CPA in latest biopsy subtracted from CPA at 1&#x02005;year post-LT, divided by time in years between the two biopsies: CPA%/year). Ishak stage progression was calculated as in latest biopsy subtracted from stage in the biopsy at 1&#x02005;year, divided by time in years&#x02014;stage &#x02018;units&#x02019;/year between the two biopsies.</p></sec><sec id="s2e"><title>Statistical analysis</title><p>Results are expressed as median and ranges. Categorical variables were compared using the &#x003c7;<sup>2</sup> or Fisher's exact tests. Continuous variables were compared by Student t test, or if not normally distributed by the Mann&#x02013;Whitney test. We compared the two randomised groups for histological, virological and clinical outcomes in a preplanned evaluation.</p><p>Statistical comparison was made by life tables (Kaplan&#x02013;Meier) and log rank testing. All the following variables associated with HCV recurrence in the literature (<xref ref-type="table" rid="GUTJNL2013305606TB1">table 1</xref>)&#x02014;except IL28B&#x02014;were evaluated in the Cox regression analysis: donor age/gender, cold/warm ischaemia time, initial and changes in immunosuppression occurrence and treatment of rejection episodes, cytomegalovirus or other infection, HDNH episodes, genotype, viral load pre-LT and 1&#x02005;year post-LT, antiviral treatment and SVR, diabetes mellitus pre-LT and post-LT, human leucocyte antigen and blood group compatibility of donor/recipient, sex match/mismatch and tacrolimus levels at 5/15/30&#x02005;days post-LT.</p><table-wrap id="GUTJNL2013305606TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Variables evaluated in the univariate analysis for the different endpoints examined</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Stage 4</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">MT</th><th align="left" rowspan="1" colspan="1">TT</th><th align="left" rowspan="1" colspan="1">p Value</th><th align="left" rowspan="1" colspan="1">CPA&#x02265;6%</th><th align="left" rowspan="1" colspan="1">CPA&#x02265;7.2%</th><th align="left" rowspan="1" colspan="1">HVPG&#x02265;10&#x02005;mm&#x02005;Hg</th><th align="left" rowspan="1" colspan="1">Decompensation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Cold/warm ischaemia time (min)</td><td align="left" rowspan="1" colspan="1">680/46</td><td align="left" rowspan="1" colspan="1">688/41</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Treatment allocation (evaluated)</td><td align="left" rowspan="1" colspan="1">54 (49)</td><td align="left" rowspan="1" colspan="1">49 (48)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Stopped azathioprine</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">16 (33%)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">0.012</td><td rowspan="1" colspan="1">0.013</td></tr><tr><td colspan="8" rowspan="1">Tacrolimus trough concentrations (ng/mL)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5&#x02005;days</td><td rowspan="1" colspan="1">7.7</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.017</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15&#x02005;days*</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">6.1</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">&#x02003;30&#x02005;days*</td><td rowspan="1" colspan="1">7.9</td><td rowspan="1" colspan="1">6.7</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">Conc. HCC</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">Conc. ALD</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">48.9&#x02005;years</td><td align="left" rowspan="1" colspan="1">50&#x02005;years</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Donor age</td><td align="left" rowspan="1" colspan="1">48.5&#x02005;years</td><td align="left" rowspan="1" colspan="1">44&#x02005;years</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">Gender mismatch</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Rejection episodes</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.0033</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.033</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Rejection treatment (courses)</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">0.002</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.038</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">HDNH</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">CMV viraemia treated</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td colspan="8" rowspan="1">Viral load logIU/mL (median)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-LT</td><td rowspan="1" colspan="1">5.29</td><td rowspan="1" colspan="1">5.36</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3&#x02005;m post-LT</td><td rowspan="1" colspan="1">6.6</td><td rowspan="1" colspan="1">6.39</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Genotype 1/1b</td><td align="left" rowspan="1" colspan="1">41%</td><td align="left" rowspan="1" colspan="1">41%</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">Antiviral treatment</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">SVR</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">NA</td></tr><tr><td colspan="8" rowspan="1">DM</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Pre-LT</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Post-LT (last follow-up)</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">0.013</td><td rowspan="1" colspan="1">0.038</td><td rowspan="1" colspan="1">0.044</td><td rowspan="1" colspan="1">NS</td><td rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p>*Median trough levels derived from all measurements up to days 15 and 30 post-LT.</p></fn><fn><p>ALD, alcoholic liver disease; CMV, cytomegalovirus; CPA, collagen proportionate area; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HDNH, histological de novo hepatitis; HVPG, hepatic venous pressure gradient; LT, liver transplantation; MT, monotherapy; NA, non-applicable; NS, non-significant; SVR, sustained virological response; TT, triple therapy.</p></fn></table-wrap-foot></table-wrap><p>A p value&#x0003c;0.05 was considered statistically significant. SPSS V.20.0 was used.</p><p>Patients were censored at the time of SVR, when analysing progression to HVPG&#x02265;10&#x02005;mm&#x02005;Hg, to CPA cut-offs of 6% and 7.2%, to first clinical decompensation event, and survival. As reported previously, sample size was calculated to be 110 patients: S4 was estimated to occur in 35% by 3&#x02005;years with a projected decrease to 10% with tacrolimus MT, and this required a sample size of 99. Considering a dropout rate of 10% (including early deaths), we concluded that 110 patients would be needed with a two-tailed test with significance at 5% and a power of 80% (1-B).<xref rid="R17" ref-type="bibr">17</xref></p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Patients&#x02019; demographic and transplant data</title><p>A total of 103 patients (89 Royal Free Hospital, eight Royal Edinburgh Infirmary and six St Vincent's Hospital) were randomised as previously documented:<xref rid="R1" ref-type="bibr">1</xref> 29 women, 74 men; 30 had HCC and 22 concomitant alcoholic liver injury. In the last follow-up, there were only two alcohol relapsers, one in each randomised arm. Two patients were coinfected with hepatitis B or D virus (remained HBV&#x02013;DNA negative in blood throughout the study).</p><p>By randomisation, 54 received MT and 49 TT. The groups were well matched at randomisation with no significant differences in preoperative, peri-operative or immediately postoperative variables: four were retransplanted early post-LT, two for hepatic artery thrombosis and one for primary non-function in the MT group; and one TT for hepatic artery thrombosis. Two MT patients were withdrawn within the first month post-LT because of side effects of treatment.</p><p>We analysed the remaining 97: 49 MT and 48 TT. Median follow-up was 96&#x02005;months (range 1&#x02013;146): 91.6&#x02005;months MT and 98.7 months TT; 15/97 (15.5%) died within 3&#x02005;years from randomisation. In all, 78/97 (80%) had a follow-up of more than 3&#x02005;years, fulfilling the sample size calculation based on Log rank testing.</p><p>Clinical characteristics were well balanced and HCV genotypes were similarly distributed. In tacrolimus MT: 20 patients genotype 1 (41%), seven genotype 2 (14%), 16 genotype 3 (33%) and six genotype 4 (12%). In TT group, the distribution was 20 patients genotype 1 (41%), one genotype 2 (2%), 19 genotype 3 (40%), seven genotype 4 (15%) and genotype 5 (2%).</p><p>Median HCV RNA levels were not significantly different, pretransplant or at 1 or 3&#x02005;months post-LT.<xref rid="R1" ref-type="bibr">1</xref> Antiviral treatment for HCV recurrence was used in 25 of 30 patients reaching stage 4 (19 MT, 11 TT), with six achieving SVR (18, 36 and 52&#x02005;months MT; 36, 38 and 40&#x02005;months TT). The median time to initiate therapy was the same in the two trial arms: 45&#x02005;months for 19 MT patients and 51&#x02005;months for 11 TT patients. All patients were treated with pegylated interferon &#x003b1;-2b 0.5&#x02005;&#x003bc;g/kg weekly escalating to 1&#x02005;&#x003bc;g/kg, and ribavirin 200&#x02005;mg escalating to 800&#x02005;mg/daily. The HDNH episodes were only diagnosed within 6&#x02005;months post-LT, and occurred in 17 MT and eight TT patients.</p><p>Tacrolimus trough levels were a median of 7.7&#x02005;ng/mL (MT) and 5&#x02005;ng/mL (TT) (p=0.03) at 5&#x02005;days; 8.5&#x02005;ng/mL (MT) and 6.1&#x02005;ng/mL (TT) (p=0.017) at 15&#x02005;days post-LT; and 7.9&#x02005;ng/mL (MT) and 6.7&#x02005;ng/mL (TT) (p=0.031) at 30&#x02005;days post-LT. The difference in median tacrolimus levels was maintained up to 6&#x02005;months post-LT: 7&#x02005;ng/mL in MT group versus 5.8&#x02005;ng/mL in TT arm (p=0.044). There was no difference at 1&#x02005;year post-LT. The median tacrolimus levels at 1&#x02005;year post-LT were not significantly different between those who discontinued azathioprine before 1&#x02005;year post-LT (7.7&#x02005;ng/mL) versus those who were still on azathioprine at that point (6.7&#x02005;ng/mL).</p><p>There were no new rejection episodes compared with those previously published:<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R9" ref-type="bibr">9</xref> During the first 3&#x02005;months, 22 MT had 42 rejection episodes and 16 received 21 courses of methylprednisolone. In comparison, 31 TT had 64 rejection episodes and 24 received 30 courses of methylprednisolone. It should be noted that after the last bolus, steroid dosage (if in TT arm) reverted to 20&#x02005;mg/day (ie, no high to low tail off of oral steroids) or none in MT arm.</p><p>The proportion of patients whose serum creatine rose to&#x02265;130&#x02005;&#x000b5;mol/L (1.5&#x02005;mg/dL) during the first 3&#x02005;months post-transplant was similar: 23% MT versus 20% TT. At the last follow-up, abnormal serum creatine (&#x0003e;1.5&#x02005;mg/dL) was noted in nine out of 37 (24%) patients alive in the MT and five out of 41 (12%) patients alive in TT group. No patient has ended up on dialysis. Incidence of diabetes post-LT was 33% MT and 31% TT.</p><p>There was no difference in numbers of biopsies and average number of biopsies/patient performed between groups. Patients&#x02019; characteristics are shown in <xref ref-type="table" rid="GUTJNL2013305606TB2">table 2</xref>. The number of patients with suitable biopsies evaluated for Ishak staging was 90/97 (45 MT/45 TT) and for CPA was 81/89 Royal Free patients (37 MT/44 TT).</p><table-wrap id="GUTJNL2013305606TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Characteristics of patients transplanted for HCV cirrhosis randomised to either tacrolimus monotherapy or triple therapy (tacrolimus, prednisolone and azathioprine)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="bottom"><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Monotherapy<break/>49</th><th align="left" rowspan="1" colspan="1">Triple therapy<break/>48</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Follow-up (median)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;96 (1&#x02013;146) m</td><td rowspan="1" colspan="1">91.6</td><td rowspan="1" colspan="1">98.7</td></tr><tr><td colspan="3" rowspan="1">Biopsies performed</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Years 1/2</td><td rowspan="1" colspan="1">34/27</td><td rowspan="1" colspan="1">40/30</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Years 3/4</td><td rowspan="1" colspan="1">26/17</td><td rowspan="1" colspan="1">27/19</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Years 5/6</td><td rowspan="1" colspan="1">18/14</td><td rowspan="1" colspan="1">16/13</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Years 7/8</td><td rowspan="1" colspan="1">11/9</td><td rowspan="1" colspan="1">10/9</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Years 9/10</td><td rowspan="1" colspan="1">2/3</td><td rowspan="1" colspan="1">2/2</td></tr><tr><td rowspan="1" colspan="1">Biopsy index*</td><td rowspan="1" colspan="1">3.31</td><td rowspan="1" colspan="1">3.48</td></tr><tr><td colspan="3" rowspan="1">Reaching Ishak stage 4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">32&#x02005;m</td><td rowspan="1" colspan="1">49&#x02005;m</td></tr><tr><td colspan="3" rowspan="1">Reaching CPA&#x02265;6%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">20/33 (61%)</td><td rowspan="1" colspan="1">13/39 (33%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">41&#x02005;m</td><td rowspan="1" colspan="1">49&#x02005;m</td></tr><tr><td colspan="3" rowspan="1">Reaching CPA&#x02265;7.2%</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">21/33</td><td rowspan="1" colspan="1">14/39</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">42&#x02005;m</td><td rowspan="1" colspan="1">51&#x02005;m</td></tr><tr><td colspan="3" rowspan="1">Reaching HVPG&#x02265;10&#x02005;mm&#x02005;Hg</td></tr><tr><td rowspan="1" colspan="1">&#x02003;N</td><td rowspan="1" colspan="1">11/33</td><td rowspan="1" colspan="1">4/31</td></tr><tr><td colspan="3" rowspan="1">Decompensated</td></tr><tr><td rowspan="1" colspan="1">&#x02003;n (months)</td><td rowspan="1" colspan="1">9 (70&#x02005;months)</td><td rowspan="1" colspan="1">4 (91&#x02005;months)</td></tr><tr><td colspan="3" rowspan="1">Deaths</td></tr><tr><td rowspan="1" colspan="1">&#x02003;n</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">7</td></tr></tbody></table><table-wrap-foot><fn><p>*Biopsy index per patient (months of follow-up divided by the number of biopsies from 1&#x02005;year onwards).</p></fn><fn><p>CPA, collagen proportionate area; HVPG, hepatic venous pressure gradient.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Factors associated with reaching Ishak stage 4 or greater</title><p>At least stage 4 was reached by 19 MT patients at a median of 32&#x02005;months: eight reached stage 4, eight stage 5 and three stage 6. Correspondingly, 11 TT patients reached stage 4 or greater at a median of 49&#x02005;months (six reached stage 5, none stage 6). Patients receiving antiviral treatment or achieving SVR were not censored as treatment in all patients was initiated after reaching Ishak stage 4 or greater. In univariate and multivariate analyses, three factors were associated with fibrosis stage &#x02265;4: randomisation to allocated MT treatment (p=0.001, OR 2.94, 95% CI 1.3 to 6.7), HDNH (p=0.015, OR 2.67, 95% CI 1.23 to 5.8) and discontinuation of azathioprine (p=0.036, OR 2.24, 95% CI 1.3 to 3.9). Patients who died without reaching stage 4 (four MT, one TT) were censored at the last biopsy with its Ishak stage. Hazard curves of MT/TT allocation (p=0.005 Mantel&#x02013;Cox) and use/discontinuation of azathioprine (p=0.003 Mantel&#x02013;Cox) are shown in <xref ref-type="fig" rid="GUTJNL2013305606F1">figure 1</xref>.</p><fig id="GUTJNL2013305606F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Hazard curves of Ishak stage 4. Hazard curves of reaching Ishak stage 4 in the two treatment arms (p=0.005 Mantel&#x02013;Cox). In all, 19 MT patients reached stage &#x02265;4 at a median of 32&#x02005;months, while 11 TT reached stage &#x02265;4 at a median of 49&#x02005;months post-LT. Sixteen patients discontinued azathioprine between 10 and 37&#x02005;months post-LT. MT, monotherapy; TT, triple therapy.</p></caption><graphic xlink:href="gutjnl-2013-305606f01"/></fig></sec><sec id="s3c"><title>Factors associated with CPA cut-offs</title><p>As previously published, CPA of 6% at 1&#x02005;year biopsy post-LT was highly predictive of clinical outcome in a larger recurrent HCV population after liver transplantation<xref rid="R3" ref-type="bibr">3</xref> and CPA of 7.2% was independently associated with portal hypertension, that is, HVPG &#x02265;6&#x02005;mm&#x02005;Hg.<xref rid="R15" ref-type="bibr">15</xref> We used the cut-off of 6% of CPA and the time to first reach CPA&#x02265;6% to compare the allocated treatments, including a multivariate analysis: 20 MT patients reached CPA&#x02265;6% (20/37 or 54%) at a median of 41&#x02005;months, while 13 TT reached CPA&#x02265;6% (13/44, 30%) at a median of 49&#x02005;months. In the multivariate analysis, allocated treatment with MT (p=0.007, OR 2.67, 95% CI 1.31 to 5.46) and HDNH (p=0.001, OR 3.27, 95% CI 1.61 to 6.6) were independently associated with CPA&#x02265;6%. For CPA&#x02265;7.2%, allocated MT treatment (p=0.004, OR 2.85, 95% CI 1.38 to 5.86), HDNH (p=0.006, OR 2.69, 95% CI 1.32 to 5.48) and discontinuation of azathioprine (p=0.011, OR 2.1, 95% CI 1.1 to 2.8) were independent factors. Hazard curves are shown in <xref ref-type="fig" rid="GUTJNL2013305606F2">figure 2</xref> for CPA cut-offs of 6% and 7.2% (p=0.002 and p=0.001 Mantel&#x02013;Cox respectively).</p><fig id="GUTJNL2013305606F2" position="float"><label>Figure&#x000a0;2</label><caption><p>Hazard curves of collagen proportionate area (CPA) 6% and 7.2%. Hazard curves of reaching CPA 6% and 7.2% with those achieving sustained virological response censored (18&#x02005;m MT, 36&#x02005;m TT, 36&#x02005;m MT, 38&#x02005;m TT, 40&#x02005;m TT, 52&#x02005;m MT) in the two treatment arms (p=0.002 for CPA 6% and p=0.001 for CPA 7.2% by Mantel&#x02013;Cox). Sixteen patients discontinued azathioprine between 10 and 37&#x02005;months post-LT. MT, monotherapy; TT, triple therapy.</p></caption><graphic xlink:href="gutjnl-2013-305606f02"/></fig></sec><sec id="s3d"><title>Factors associated with portal hypertension</title><p>HVPG measurement was performed combined with transjugular biopsies in 33 MT and 31 TT patients. These represent 78% MT and 72% TT patients surviving at 1&#x02005;year at the Royal Free Hospital as HVPG was not measured in Edinburgh or Dublin. There were 154 HVPG measurements post-LT: 64 at a median of 17&#x02005;months, 41 at a median of 31&#x02005;m, 30 at a median of 48&#x02005;m, 15 at a median of 63&#x02005;m and four at a median of 86&#x02005;m. HVPG&#x02265;10&#x02005;mm&#x02005;Hg (clinically significant portal hypertension) was reached in 11 MT compared with four TT patients. Cox regression analysis revealed HDNH (p=0.015, OR 3.68, 95% CI 1.26 to 10.69) and allocated MT treatment (p=0.017, OR 4.13, 95% CI 1.28 to 13.29) to be independently associated with HVPG&#x02265;10&#x02005;mm&#x02005;Hg: hazard curves are shown in <xref ref-type="fig" rid="GUTJNL2013305606F3">figure 3</xref> (p=0.027 Mantel&#x02013;Cox and 0.019 Breslow).</p><fig id="GUTJNL2013305606F3" position="float"><label>Figure&#x000a0;3</label><caption><p>(A) Hazard curves of developing hepatic venous pressure gradient (HVPG)&#x02265;10&#x02005;mm&#x02005;Hg and clinical decompensation. Hazard curves of developing HVPG&#x02265;10&#x02005;mm&#x02005;Hg in the two treatment arms (p=0.019 by Breslow) in 33 MT and 31 TT. In all, 11 MT reached HVPG&#x02265;10&#x02005;mm&#x02005;Hg, compared with four TT. Patients achieving sustained virological response (SVR) before reaching HVPG&#x02265;10&#x02005;mm&#x02005;Hg were censored at the time of SVR. (B) Hazard curves of decompensation, defined as whichever occurred first of ascites/hydrothorax, variceal bleeding or encephalopathy, in our trial cohort (p=0.037 by Breslow). Decompensation occurred in 13 patients: nine MT at a mean of 70&#x02005;m and four TT at a mean time of 91&#x02005;m. Patients achieving SVR were censored at the time of SVR. MT, monotherapy; TT, triple therapy.</p></caption><graphic xlink:href="gutjnl-2013-305606f03"/></fig></sec><sec id="s3e"><title>Factors associated with clinical decompensation</title><p>Decompensation occurred in 13 patients (all reached stage 5/6 at the time of decompensation) at a mean of 82&#x02005;months: nine MT patients (seven ascites, one variceal bleeding, one encephalopathy) at a mean of 70&#x02005;m and four TT patients (three ascites, one encephalopathy) at a mean time of 91&#x02005;m. Hazard curves are shown in <xref ref-type="fig" rid="GUTJNL2013305606F4">figure 3</xref> (p=0.015 by Mantel&#x02013;Cox, 0.037 Breslow).</p><fig id="GUTJNL2013305606F4" position="float"><label>Figure&#x000a0;4</label><caption><p>Fibrosis progression over time based on collagen proportionate area (CPA) and Ishak stage. Mean fibrosis according to time post-LT based on CPA and Ishak stage. Overall, 310 biopsies were evaluated in 49 MT and 48 TT: Median CPA fibrosis progression rate was 1.5%/year. Each box plot shows the median value, the IQR and the range of CPA each year. Ishak stage progression is presented as mean values &#x000b1;2&#x02009;SD to allow comparison with work from others. MT, monotherapy; TT, triple therapy.</p></caption><graphic xlink:href="gutjnl-2013-305606f04"/></fig><p>In the Cox regression analysis, allocated MT treatment was the only statistically significant factor associated with clinical decompensation (p=0.047, OR 3.23, 95% CI 1.01 to 10.3).</p></sec><sec id="s3f"><title>Fibrosis progression rate</title><p>We evaluated 310 biopsies for Ishak stage and 289 biopsies for CPA due to inadequate material for restaining. The number of biopsies performed every year were: 74 in year 1 (34 MT/40 TT), 57 in year 2 (27 MT/30 TT), 53 in year 3 (26 MT/27 TT), 36 in year 4 (17 MT/19 TT), 34 in year 5, (18 MT/16 TT), 27 in year 6 (14 MT/13 TT), 21 in year 7 (11 MT/10 TT), 18 in year 8 (9 MT/9 TT), 4 in year 9 (2 MT/2 TT) and 5 in year 10 (3 MT/2 TT). Fibrosis progression according to CPA and stage progression over time are shown in figure 4. Median CPA fibrosis progression rate was 0.7%/year (0.74%/year MT, 0.67%/year TT). Mean stages per year (given for comparison with published studies) were: at 1&#x02005;year (1.45), 2&#x02005;years (2.1), 3&#x02005;years (2.38), 4&#x02005;years (2.86), 5&#x02005;years (3), 6&#x02005;years (3.2), 7&#x02005;years (3.2) 8&#x02005;years (3.47), 9&#x02005;years (4) and 10&#x02005;years (5). Mean stages for MT group were: 1.58, 2.37, 2.77, 3.18, 3.28, 3.66, 3.22, 4, 5 and 5, and for TT group were: 1.3, 1.9, 2, 2.57, 2.6, 2.77, 3, 2.87, 3 and 3 for years 1&#x02013;10 post-LT respectively. Mean Ishak stage progression rate was 0.2 stage U/year (0.3 stage U/year in MT, 0.2 stage U/year TT).</p><p>Fibrosis progression rate was not significantly different between patients requiring steroids boluses for acute cellular rejection or not. Median CPA fibrosis progression rate was 0.72%/year in those requiring steroids boluses and 0.69%/year in those not treated for acute cellular rejection. Mean Ishak stage progression rate was 0.2 stage U/year in both groups.</p></sec><sec id="s3g"><title>Factors associated with early survival overall survival and graft survival</title><p>In the TT group three patients died within 3&#x02005;months: one patient after retransplant (sepsis&#x02014;2&#x02005;days) and two at 1&#x02005;month from sepsis and multiple organ failure. There were another four deaths: one due to non-liver related causes at 6&#x02005;months, two from recurrent HCV disease (30 and 42&#x02005;months) and one at 95&#x02005;months from recurrent HCC.</p><p>In the MT group, 14 patients died: five from sepsis and multiple organ failure (0.3, 0.3, 0.6, 1 and 4&#x02005;months), one from graft failure (0.5&#x02005;months), one from pulmonary hypertension (0.2&#x02005;months), one from ductopenic rejection (18&#x02005;months) and one from recurrent HCV disease (30&#x02005;months). Six more patients died in the current update: three from recurrent HCV disease (36, 37 and 72&#x02005;months post-LT), one from embolic stroke (56&#x02005;months) and one from lung adenocarcinoma (96&#x02005;months).</p><p>Overall, mortality in the randomised 103 patients favoured TT patients (p=0.036) as well as the 97 currently evaluated (p=0.025). However, there was no statistically significant factor associated with mortality in the multivariate analysis, and no significant difference in deaths due to HCV recurrence.</p><p>Similarly, graft survival favoured the TT arm (p=0.019): 15 MT and seven TT patients died, and five MT/4 TT were retransplanted, but this difference was not due to recurrent disease.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this final evaluation of our randomised study,<xref rid="R1" ref-type="bibr">1</xref> the median follow-up was just over 8&#x02005;years, the longest published to date following liver transplantation in a randomised trial concerning HCV cirrhosis,<xref rid="R6" ref-type="bibr">6</xref>
<xref rid="R18" ref-type="bibr">18</xref> and given the numbers who either died within 3&#x02005;years or survived more than 3&#x02005;years (used for sample size calculation), this allowed a robust evaluation of clinical outcomes of recurrent HCV disease. Our outcomes included first clinical decompensation event (evaluated for the first time), HVPG and fibrosis progression defined by CPA and Ishak stage.</p><p>Fibrosis progression after liver transplantation for hepatitis C related cirrhosis has been studied several times<xref rid="R19" ref-type="bibr">19&#x02013;24</xref> mainly by assessing changes in Ishak/Metavir scores. Fibrosis progression is well recognised to have prognostic significance before<xref rid="R25" ref-type="bibr">25</xref> and after transplantation.<xref rid="R4" ref-type="bibr">4</xref> The overall rate of increase of disease stage described by changes in Ishak staging in our total trial population is similar or lower than fibrosis rates previously described.<xref rid="R22" ref-type="bibr">22&#x02013;24</xref> The mean fibrosis Ishak stage was 1.45 and 2.1 in years 1 and 2 post-LT in our whole cohort, and 1.3 and 1.9 at years 1 and 2 post-LT respectively for the TT group, which are as low as those recently published in patients receiving sirolimus (which may have antifibrotic properties) compared with historical controls (0.62 and 1.15 metavir in year 1 and 2 biopsies, respectively).<xref rid="R26" ref-type="bibr">26</xref></p><p>The relatively low overall rate of increase of disease stage in our trial population most likely reflects use of combined therapy of tacrolimus with azathioprine and steroids and/or the generally lower trough levels of tacrolimus achieved.<xref rid="R2" ref-type="bibr">2</xref> Since our first publication, we have shown that CPA assessment in HCV post-LT patients correlates with both Ishak stage scores and HVPG, with greater percentage changes in CPA, compared with HVPG in early portal hypertension.<xref rid="R15" ref-type="bibr">15</xref> Moreover, CPA at 1&#x02005;year biopsy post-LT is highly predictive of clinical outcome in HCV transplanted patients and better than Ishak stage or HVPG.<xref rid="R3" ref-type="bibr">3</xref> In the current update, MT and HDNH were independently associated with reaching CPA cut-offs of 6%<xref rid="R3" ref-type="bibr">3</xref> and 7.2%, the latter corresponding to HVPG&#x02265;6&#x02005;mm&#x02005;Hg,<xref rid="R15" ref-type="bibr">15</xref> reinforcing both the value of CPA and validating these cut-offs as endpoints.<xref rid="R27" ref-type="bibr">27</xref></p><p>As in our first publication,<xref rid="R1" ref-type="bibr">1</xref> outcomes favouring the TT group are supported by HVPG measurements.<xref rid="R28" ref-type="bibr">28</xref> There was more clinically significant portal hypertension (associated with advent of complications and worse survival)<xref rid="R29" ref-type="bibr">29</xref> in the MT group (11 patients reached HVPG&#x02265;10&#x02005;mm&#x02005;Hg, compared with four TT) corroborating the more severe fibrosis found in MT patients.</p><p>The significance of HDNH is again confirmed by us<xref rid="R1" ref-type="bibr">1</xref>
<xref rid="R2" ref-type="bibr">2</xref>
<xref rid="R4" ref-type="bibr">4</xref> and others<xref rid="R30" ref-type="bibr">30</xref> as this was independently associated with Ishak stage 4, but also CPA cut-offs for decompensation and HVPG.</p><p>A limitation in this study could be the lack of evaluation of recipient IL28B polymorphism, which was also missing in the recent sirolimus study.<xref rid="R26" ref-type="bibr">26</xref> Some studies suggest a higher recurrence rate of HCV hepatitis with the poor interferon response allele of IL28B in the recipient.<xref rid="R31" ref-type="bibr">31</xref>
<xref rid="R32" ref-type="bibr">32</xref> However, randomisation will most likely have balanced out the more favourable polymorphism, which in any case is under represented in liver transplant populations.<xref rid="R32" ref-type="bibr">32</xref> Moreover, IL28B was not significantly associated with either overall or liver related mortality in one study,<xref rid="R32" ref-type="bibr">32</xref> and there has been a selection bias in most studies, as only patients with biopsies were evaluated, that is, not every patient with recurrent hepatitis C was biopsied.<xref rid="R31" ref-type="bibr">31</xref> Moreover, no study evaluated immunosuppression when analysing severity of recurrence.<xref rid="R31" ref-type="bibr">31&#x02013;35</xref> Last, some studies do not show an association of recipient IL28B with worse HCV disease recurrence.<xref rid="R36" ref-type="bibr">36</xref></p><p>Our TT group received azathioprine, which many centres have substituted with mycophenalate which however may worsen fibrosis progression compared with azathioprine.<xref rid="R5" ref-type="bibr">5</xref> In addition, low dose maintenance steroids may also favour less severe recurrence and improve graft survival.<xref rid="R37" ref-type="bibr">37&#x02013;39</xref> However, the use of steroids in transplantation for HCV cirrhosis remains an unresolved issue.<xref rid="R6" ref-type="bibr">6</xref> Interestingly, although steroids boluses greatly increase HCV RNA levels,<xref rid="R40" ref-type="bibr">40</xref> our TT group had more rejection episodes treated with high dose steroids,<xref rid="R9" ref-type="bibr">9</xref> so it may be that the long term benefit of immune modulation with steroids is more important than the risk of HCV activation following steroid boluses for rejection. Indeed, a recent study has shown no distinct advantage of steroid avoidance<xref rid="R18" ref-type="bibr">18</xref> and another group have shown that steroid-free immunosuppression leads to a higher rate of chronic rejection.<xref rid="R41" ref-type="bibr">41</xref></p><p>In conclusion, long term maintenance immunosuppression with tacrolimus, azathioprine and shorter term prednisolone in HCV cirrhosis recipients resulted in a slower onset of histological severe fibrosis confirmed by Ishak stage and CPA, less portal hypertension, and less clinical decompensation compared with tacrolimus alone. Our results support and extend our initial report.<xref rid="R1" ref-type="bibr">1</xref> Given that our TT arm has the lowest fibrosis progression rate published so far&#x02014;lower than sirolimus&#x02014;<xref rid="R26" ref-type="bibr">26</xref> and that there is some evidence that azathioprine is better than mycophenalate,<xref rid="R5" ref-type="bibr">5</xref> our TT regimen could be considered as a first choice for patients transplanted for HCV cirrhosis, until other evidence proves otherwise.</p></sec></body><back><fn-group><fn><p><bold>Competing interests:</bold> AKB and APD have an unrestricted educational grant from Pfizer.</p></fn><fn><p><bold>Ethics approval:</bold> The hospital ethics committees at each site.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manousou</surname><given-names>P</given-names></name><name><surname>Samonakis</surname><given-names>D</given-names></name><name><surname>Cholongitas</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy</article-title>. <source>Liver Transpl</source>
<year>2009</year>;<volume>15</volume>:<fpage>1783</fpage>&#x02013;<lpage>91</lpage><pub-id pub-id-type="pmid">19938143</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonakis</surname><given-names>DN</given-names></name><name><surname>Triantos</surname><given-names>CK</given-names></name><name><surname>Thalheimer</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation</article-title>. <source>Liver Transpl</source>
<year>2005</year>;<volume>11</volume>:<fpage>386</fpage>&#x02013;<lpage>95</lpage><pub-id pub-id-type="pmid">15776454</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manousou</surname><given-names>P</given-names></name><name><surname>Dhillon</surname><given-names>AP</given-names></name><name><surname>Isgro</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation</article-title>. <source>Liver Transpl</source>
<year>2011</year>;<volume>17</volume>:<fpage>178</fpage>&#x02013;<lpage>88</lpage><pub-id pub-id-type="pmid">21280191</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manousou</surname><given-names>P</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name><name><surname>Sochatzis</surname><given-names>ET</given-names></name><etal/></person-group>
<article-title>Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation</article-title>. <source>J. Hepatol</source>
<year>2013</year>;<volume>58</volume>:<fpage>962</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">23262247</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germani</surname><given-names>G</given-names></name><name><surname>Pleguezuelo</surname><given-names>M</given-names></name><name><surname>Villamil</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil</article-title>. <source>Am J Transplant</source>
<year>2009</year>;<volume>9</volume>:<fpage>1725</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="pmid">19538488</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonakis</surname><given-names>DN</given-names></name><name><surname>Germani</surname><given-names>G</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name></person-group>
<article-title>Immunosuppression and HCV recurrence after liver transplantation</article-title>. <source>J Hepatol</source>
<year>2012</year>;<volume>56</volume>:<fpage>973</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="pmid">21963518</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Royuela</surname><given-names>A</given-names></name><name><surname>Zamora</surname><given-names>J</given-names></name></person-group>
<article-title>Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis</article-title>. <source>Liver Transpl</source>
<year>2007</year>;<volume>13</volume>:<fpage>21</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">17192906</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakumu</surname><given-names>S</given-names></name><name><surname>Takayanagi</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C</article-title>. <source>J Gastroenterol Hepatol</source>
<year>1997</year>;<volume>12</volume>:<fpage>62</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">9076626</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonakis</surname><given-names>DN</given-names></name><name><surname>Mela</surname><given-names>M</given-names></name><name><surname>Quaglia</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis</article-title>. <source>Transpl Infect Dis</source>
<year>2006</year>;<volume>8</volume>:<fpage>3</fpage>&#x02013;<lpage>12</lpage><pub-id pub-id-type="pmid">16623815</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuyver</surname><given-names>L</given-names></name><name><surname>Rossau</surname><given-names>R</given-names></name><name><surname>Wyseur</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay</article-title>. <source>J Gen Virol</source>
<year>1993</year>;<volume>74</volume><issue>(Pt 6)</issue>:<fpage>1093</fpage>&#x02013;<lpage>102</lpage><pub-id pub-id-type="pmid">8389799</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>KK</given-names></name><name><surname>Resnick</surname><given-names>RM</given-names></name><name><surname>Myers</surname><given-names>TW</given-names></name></person-group>
<article-title>Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay</article-title>. <source>J Clin Microbiol</source>
<year>1993</year>;<volume>31</volume>:<fpage>882</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">8385151</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishak</surname><given-names>K</given-names></name><name><surname>Baptista</surname><given-names>A</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Histological grading and staging of chronic hepatitis</article-title>. <source>J Hepatol</source>
<year>1995</year>;<volume>22</volume>:<fpage>696</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">7560864</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cholongitas</surname><given-names>E</given-names></name><name><surname>Quaglia</surname><given-names>A</given-names></name><name><surname>Samonakis</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Transjugular liver biopsy: how good is it for accurate histological interpretation?</article-title>
<source>Gut</source>
<year>2006</year>;<volume>55</volume>:<fpage>1789</fpage>&#x02013;<lpage>94</lpage><pub-id pub-id-type="pmid">16636018</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>AR</given-names></name><name><surname>Lin</surname><given-names>XZ</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name></person-group>
<article-title>The normal adult human liver biopsy: a quantitative reference standard</article-title>. <source>Hepatology</source>
<year>1998</year>;<volume>28</volume>:<fpage>323</fpage>&#x02013;<lpage>31</lpage><pub-id pub-id-type="pmid">9695993</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvaruso</surname><given-names>V</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name><name><surname>Standish</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient</article-title>. <source>Hepatology</source>
<year>2009</year>;<volume>49</volume>:<fpage>1236</fpage>&#x02013;<lpage>44</lpage><pub-id pub-id-type="pmid">19133646</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>GS</given-names></name><name><surname>Hudson</surname><given-names>M</given-names></name><name><surname>Burroughs</surname><given-names>AK</given-names></name><etal/></person-group>
<article-title>Grading of cellular rejection after orthotopic liver transplantation</article-title>. <source>Hepatology</source>
<year>1995</year>;<volume>21</volume>:<fpage>46</fpage>&#x02013;<lpage>57</lpage><pub-id pub-id-type="pmid">7806168</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>LS</given-names></name></person-group>
<article-title>Tables of the number of patients required in clinical trials using the logrank test</article-title>. <source>Stat Med</source>
<year>1982</year>;<volume>1</volume>:<fpage>121</fpage>&#x02013;<lpage>9</lpage><pub-id pub-id-type="pmid">7187087</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klintmalm</surname><given-names>GB</given-names></name><name><surname>Davis</surname><given-names>GL</given-names></name><name><surname>Teperman</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C</article-title>. <source>Liver Transpl</source>
<year>2011</year>;<volume>17</volume>:<fpage>1394</fpage>&#x02013;<lpage>403</lpage><pub-id pub-id-type="pmid">21850690</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>N</given-names></name><name><surname>Shiffman</surname><given-names>ML</given-names></name><name><surname>Stravitz</surname><given-names>RT</given-names></name><etal/></person-group>
<article-title>A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation</article-title>. <source>Liver Transpl</source>
<year>2007</year>;<volume>13</volume>:<fpage>975</fpage>&#x02013;<lpage>83</lpage><pub-id pub-id-type="pmid">17600360</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samonakis</surname><given-names>DN</given-names></name><name><surname>Cholongitas</surname><given-names>E</given-names></name><name><surname>Thalheimer</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis</article-title>. <source>Liver Transpl</source>
<year>2007</year>;<volume>13</volume>:<fpage>1305</fpage>&#x02013;<lpage>11</lpage><pub-id pub-id-type="pmid">17763383</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos-Orozco</surname><given-names>JF</given-names></name><name><surname>Yosephy</surname><given-names>A</given-names></name><name><surname>Noble</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course</article-title>. <source>Liver Transpl</source>
<year>2009</year>;<volume>15</volume>:<fpage>1872</fpage>&#x02013;<lpage>81</lpage><pub-id pub-id-type="pmid">19938138</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Ferrell</surname><given-names>L</given-names></name><name><surname>Watson</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>HCV-related fibrosis progression following liver transplantation: increase in recent years</article-title>. <source>J Hepatol</source>
<year>2000</year>;<volume>32</volume>:<fpage>673</fpage>&#x02013;<lpage>84</lpage><pub-id pub-id-type="pmid">10782918</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>UP</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Bahra</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Fibrosis progression after liver transplantation in patients with recurrent hepatitis C</article-title>. <source>J Hepatol</source>
<year>2004</year>;<volume>41</volume>:<fpage>830</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">15519657</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wali</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>RF</given-names></name><name><surname>Gow</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C</article-title>. <source>Gut</source>
<year>2002</year>;<volume>51</volume>:<fpage>248</fpage>&#x02013;<lpage>52</lpage><pub-id pub-id-type="pmid">12117889</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poynard</surname><given-names>T</given-names></name><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Opolon</surname><given-names>P</given-names></name></person-group>
<article-title>Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups</article-title>. <source>Lancet</source>
<year>1997</year>;<volume>349</volume>:<fpage>825</fpage>&#x02013;<lpage>32</lpage><pub-id pub-id-type="pmid">9121257</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>GJ</given-names></name><name><surname>Trotter</surname><given-names>JF</given-names></name><name><surname>Klintmalm</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression</article-title>. <source>Am J Transplant</source>
<year>2011</year>;<volume>11</volume>:<fpage>2379</fpage>&#x02013;<lpage>87</lpage><pub-id pub-id-type="pmid">21967703</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germani</surname><given-names>G</given-names></name><name><surname>Hytiroglou</surname><given-names>P</given-names></name><name><surname>Fotiadu</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Assessment of fibrosis and cirrhosis in liver biopsies: an update</article-title>. <source>Semin Liver Dis</source>
<year>2011</year>;<volume>31</volume>:<fpage>82</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="pmid">21344353</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burroughs</surname><given-names>AK</given-names></name><name><surname>Groszmann</surname><given-names>R</given-names></name><name><surname>Bosch</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?</article-title>
<source>Gut</source>
<year>2002</year>;<volume>50</volume>:<fpage>425</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">11839726</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ripoll</surname><given-names>C</given-names></name><name><surname>Groszmann</surname><given-names>R</given-names></name><name><surname>Garcia-Tsao</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis</article-title>. <source>Gastroenterology</source>
<year>2007</year>;<volume>133</volume>:<fpage>481</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">17681169</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Prieto</surname><given-names>M</given-names></name><name><surname>San Juan</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients</article-title>. <source>Hepatology</source>
<year>2002</year>;<volume>36</volume>:<fpage>202</fpage>&#x02013;<lpage>10</lpage><pub-id pub-id-type="pmid">12085366</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allam</surname><given-names>SR</given-names></name><name><surname>Kruger</surname><given-names>B</given-names></name><name><surname>Mehrotra</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation</article-title>. <source>PLoS ONE</source>
<year>2013</year>;<volume>8</volume>:<fpage>e54854</fpage><pub-id pub-id-type="pmid">23382988</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charlton</surname><given-names>MR</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><name><surname>Veldt</surname><given-names>BJ</given-names></name><etal/></person-group>
<article-title>Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection</article-title>. <source>Hepatology</source>
<year>2011</year>;<volume>53</volume>:<fpage>317</fpage>&#x02013;<lpage>24</lpage><pub-id pub-id-type="pmid">21254179</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte-Rojo</surname><given-names>A</given-names></name><name><surname>Veldt</surname><given-names>BJ</given-names></name><name><surname>Goldstein</surname><given-names>DD</given-names></name><etal/></person-group>
<article-title>The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables</article-title>. <source>Transplantation</source>
<year>2012</year>;<volume>94</volume>:<fpage>197</fpage>&#x02013;<lpage>203</lpage><pub-id pub-id-type="pmid">22766768</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eurich</surname><given-names>D</given-names></name><name><surname>Boas-Knoop</surname><given-names>S</given-names></name><name><surname>Ruehl</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation</article-title>. <source>Liver Transpl</source>
<year>2011</year>;<volume>17</volume>:<fpage>289</fpage>&#x02013;<lpage>98</lpage><pub-id pub-id-type="pmid">21384511</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisneros</surname><given-names>E</given-names></name><name><surname>Banos</surname><given-names>I</given-names></name><name><surname>Citores</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860</article-title>. <source>Transplantation</source>
<year>2012</year>;<volume>94</volume>:<fpage>275</fpage>&#x02013;<lpage>80</lpage><pub-id pub-id-type="pmid">22790387</pub-id></mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>CM</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><name><surname>Doehring</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection</article-title>. <source>J Hepatol</source>
<year>2011</year>;<volume>55</volume>:<fpage>322</fpage>&#x02013;<lpage>7</lpage><pub-id pub-id-type="pmid">21147186</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berenguer</surname><given-names>M</given-names></name><name><surname>Crippin</surname><given-names>J</given-names></name><name><surname>Gish</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>A model to predict severe HCV-related disease following liver transplantation</article-title>. <source>Hepatology</source>
<year>2003</year>;<volume>38</volume>:<fpage>34</fpage>&#x02013;<lpage>41</lpage><pub-id pub-id-type="pmid">12829984</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivarelli</surname><given-names>M</given-names></name><name><surname>Burra</surname><given-names>P</given-names></name><name><surname>Barba</surname><given-names>GL</given-names></name><etal/></person-group>
<article-title>Influence of steroids on HCV recurrence after liver transplantation: a prospective study</article-title>. <source>J Hepatol</source>
<year>2007</year>;<volume>47</volume>:<fpage>793</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">17928091</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brillanti</surname><given-names>S</given-names></name><name><surname>Vivarelli</surname><given-names>M</given-names></name><name><surname>De Ruvo</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation</article-title>. <source>Liver Transpl</source>
<year>2002</year>;<volume>8</volume>:<fpage>884</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">12360428</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gane</surname><given-names>EJ</given-names></name><name><surname>Naoumov</surname><given-names>NV</given-names></name><name><surname>Qian</surname><given-names>KP</given-names></name><etal/></person-group>
<article-title>A longitudinal analysis of hepatitis C virus replication following liver transplantation</article-title>. <source>Gastroenterology</source>
<year>1996</year>;<volume>110</volume>:<fpage>167</fpage>&#x02013;<lpage>77</lpage><pub-id pub-id-type="pmid">8536853</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiler</surname><given-names>N</given-names></name><name><surname>Thrun</surname><given-names>I</given-names></name><name><surname>Hoppe-Lotichius</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial</article-title>. <source>Transplantation</source>
<year>2010</year>;<volume>90</volume>:<fpage>1562</fpage>&#x02013;<lpage>6</lpage><pub-id pub-id-type="pmid">21048536</pub-id></mixed-citation></ref></ref-list></back></article>